1
Return

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances

delete2026-07-27
delete0
PRE
AI
L
Luyuan Li *
G
Genevieve Bertolet
J
Josiane E. Eid
W
William D. Tap
A
Andrew J. Wagner
A
Anthony P. Conley
F
Francis J. Hornicek
Z
Zhenfeng Duan
E
Emanuela Palmerini
J
Jonathan C. Trent *
DOI：10.1016/j.ctrv.2026.103197delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Chondrosarcoma remains largely resistant to chemo- and radiotherapy. • Histologic grade and surgical margins determine prognosis. • IDH inhibitors demonstrate durable disease control in clinical trials. • DR5 agonist therapy shows progression-free survival benefit in a randomized trial. • Targeted therapies are advancing precision treatment strategies.

Journal

Cancer Treatment Reviews cover
Cancer Treatment Reviews
IF:
10.5
Papers:
2.8K
Citations:
1.3W

Organization

M
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
Scholars:
29
Papers: 19
Citations: 1
N
north alabama medical center
Scholars:
7
Papers: 7
Citations: 0
H
harvard medical school
Scholars:
4.6K
Papers: 2.1K
Citations: 2
T
The University of Texas MD Anderson Cancer Center
Scholars:
3.3K
Papers: 731
Citations: 5.1W
U
university of miami
Scholars:
3.3W
Papers: 2.5W
Citations: 32
Cited Papers

Cited Papers

Citing Papers

Citing Papers